Free Newsletter
VC: Prestwick brings in $60M in third round
The two-week venture capital total is $147.2 million.
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Prestwick Pharmaceuticals
|
$60M
|
Warburg Pincus |
Prestwick is developing treatments for central nervous system disorders. |
|
EnteroMedics
|
$45.2M
|
InterWest Partners |
EnteroMedics is developing devices for the treatment of obesity and gastrointestinal disorders. |
|
Transpharma Medical
|
$18M
|
Argonaut |
Transpharma is developing a proprietary active transdermal drug delivery technology. |
|
Lux Biosciences
|
$13M
|
Prospect Venture Partners |
Lux specializes in ophthalmic diseases. This brings their first round total to $49 million. |
|
Elusys Therapeutics
|
$11M
|
MedImmune |
Elusys is developing targeted anti-infective therapeutics. |
More stories about Venture Capital central nervous system obesity MedImmune drug delivery technology
